一个老年患者的levofloxacin诱导的动力障碍与多阳性炎的粒状瘤
İrada İbramkhalilova1, Fatih Albayrak2, Zeynel Abidin Sayiner3
1Department of Rheumatology, Sanko University, Gaziantep, Turkey.
BMJ case reports
|December 31, 2025
概括
利沃素可以引起罕见的运动障碍,如震和动力障碍,特别是在老年患者中. 迅速停止这种抗生素导致一个粒状多炎患者的症状迅速消失.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 列沃素是一种诺基诺类抗生素,通常用于社区获得的肺炎.
- 运动障碍是诺基诺的罕见但已知的不良影响.
- 该患者患有粒状多炎,并接受免疫抑制疗法.
研究的目的:
- 报告一种勒沃素诱导的运动障碍病例.
- 讨论潜在的机制和临床影响.
主要方法:
- 在开始服用levofloxacin后,患有新发和动力障碍的患者的病例介绍.
- 进行了临床检查,实验室测试和脑部成像.
- 关于诺基诺诱导的运动障碍的文献综述.
主要成果:
- 患者在开始服用勒沃素后24小时内出现了普遍和动力障碍.
- 神经学检查显示了合唱形式的运动和步态障碍.
- 症状在停止服用levofloxacin后的一周内迅速消失.
结论:
- 列沃素可以诱导运动障碍,特别是在老年或并发症患者中.
- 潜在的机制包括GABA-A受体抑制和NMDA受体激活.
- 临床医生应该意识到诺基诺的神经毒性作为潜在的副作用.
相关概念视频
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
216
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
216
Drug Dosing: Geriatric Patients
206
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206
Pharmacodynamics in Geriatric Patients: Effects of Age
174
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
174
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
209
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
209
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
205
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
205
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
178
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
178


